Cargando…
Gaucher disease in Syrian children: common mutations identification and clinical futures
BACKGROUND AND OBJECTIVES: Gaucher disease (GD) is caused by the deficiency of glucosidase beta acid (GBA). Three clinical forms of GD are available. Some mutations in the GBA gene have a high frequency in specific populations. The aim of this study was to analyze the characteristics of phenotypes a...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
King Faisal Specialist Hospital and Research Centre
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074127/ https://www.ncbi.nlm.nih.gov/pubmed/26336018 http://dx.doi.org/10.5144/0256-4947.2015.127 |
_version_ | 1783344337352916992 |
---|---|
author | Alasmar, Diana |
author_facet | Alasmar, Diana |
author_sort | Alasmar, Diana |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: Gaucher disease (GD) is caused by the deficiency of glucosidase beta acid (GBA). Three clinical forms of GD are available. Some mutations in the GBA gene have a high frequency in specific populations. The aim of this study was to analyze the characteristics of phenotypes and genotypes of GD in Syrian pediatric patients and assess whether a genotype-phenotype relationship could be helpful in treatment decision-making. DESIGN AND SETTINGS: A cross-sectional clinical genetic study of 19 Syrian children admitted to Children’s Hospital, Damascus University. PATIENTS AND METHODS: Nineteen Syrian children with GD were enrolled in the study; DNA was extracted from peripheral blood leukocytes. The GBA gene was amplified by polymerase chain reaction, and the 9 most common mutations were studied using a Gaucher Disease Strip Assay (ViennaLab Diagnostics GmbH, Vienna, Austria). RESULTS: The majority of children had an early age of onset. A total of 17 patients presented severe hematological and skeletal complications. Neurological involvement was encountered in 2 patients. Twelve patients (63, 2%) were homozygous for the L444P mutation, 1 patient (5.3%) was homozygous for the N370S mutation, and 1 patient (5.3%) was heterozygous for the N370S mutation. Five patients (26.3%) had unknown mutations. CONCLUSION: L444P/L444P was the most common genotype in the studied patients. GD3 with severe visceral presentation in childhood was the dominant phenotype; N370S was found in the heterozygote state in 1 case and in the homozygote state in 1 case. This phenotype and genotype pattern is encountered in the Middle East. There was no genotype-phenotype correlation. |
format | Online Article Text |
id | pubmed-6074127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | King Faisal Specialist Hospital and Research Centre |
record_format | MEDLINE/PubMed |
spelling | pubmed-60741272018-09-21 Gaucher disease in Syrian children: common mutations identification and clinical futures Alasmar, Diana Ann Saudi Med Original Article BACKGROUND AND OBJECTIVES: Gaucher disease (GD) is caused by the deficiency of glucosidase beta acid (GBA). Three clinical forms of GD are available. Some mutations in the GBA gene have a high frequency in specific populations. The aim of this study was to analyze the characteristics of phenotypes and genotypes of GD in Syrian pediatric patients and assess whether a genotype-phenotype relationship could be helpful in treatment decision-making. DESIGN AND SETTINGS: A cross-sectional clinical genetic study of 19 Syrian children admitted to Children’s Hospital, Damascus University. PATIENTS AND METHODS: Nineteen Syrian children with GD were enrolled in the study; DNA was extracted from peripheral blood leukocytes. The GBA gene was amplified by polymerase chain reaction, and the 9 most common mutations were studied using a Gaucher Disease Strip Assay (ViennaLab Diagnostics GmbH, Vienna, Austria). RESULTS: The majority of children had an early age of onset. A total of 17 patients presented severe hematological and skeletal complications. Neurological involvement was encountered in 2 patients. Twelve patients (63, 2%) were homozygous for the L444P mutation, 1 patient (5.3%) was homozygous for the N370S mutation, and 1 patient (5.3%) was heterozygous for the N370S mutation. Five patients (26.3%) had unknown mutations. CONCLUSION: L444P/L444P was the most common genotype in the studied patients. GD3 with severe visceral presentation in childhood was the dominant phenotype; N370S was found in the heterozygote state in 1 case and in the homozygote state in 1 case. This phenotype and genotype pattern is encountered in the Middle East. There was no genotype-phenotype correlation. King Faisal Specialist Hospital and Research Centre 2015 /pmc/articles/PMC6074127/ /pubmed/26336018 http://dx.doi.org/10.5144/0256-4947.2015.127 Text en Copyright © 2015, Annals of Saudi Medicine This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Alasmar, Diana Gaucher disease in Syrian children: common mutations identification and clinical futures |
title | Gaucher disease in Syrian children: common mutations identification and clinical futures |
title_full | Gaucher disease in Syrian children: common mutations identification and clinical futures |
title_fullStr | Gaucher disease in Syrian children: common mutations identification and clinical futures |
title_full_unstemmed | Gaucher disease in Syrian children: common mutations identification and clinical futures |
title_short | Gaucher disease in Syrian children: common mutations identification and clinical futures |
title_sort | gaucher disease in syrian children: common mutations identification and clinical futures |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074127/ https://www.ncbi.nlm.nih.gov/pubmed/26336018 http://dx.doi.org/10.5144/0256-4947.2015.127 |
work_keys_str_mv | AT alasmardiana gaucherdiseaseinsyrianchildrencommonmutationsidentificationandclinicalfutures |